MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model Ellson, Ivan Martorell Marugán, Jordi Carmona Sáez, Pedro Ramos Mejía, Verónica Accurately predicting patient outcomes is essential for optimizing treatment and improving outcomes in pediatric acute myeloid leukemia (AML). In recent years, microRNAs have emerged as a promising prognostic marker, with a growing body of evidence supporting their potential predictive value. We systematically reviewed all previous studies that have analyzed the expression of microRNAs as predictors of survival in pediatricAMLand found 16 microRNAs and 4 microRNAsignatures previously proposed as predictors of survival. We then used a public access cohort of 1414 pediatric AML patients from the TARGET project to develop a new predictive model using penalized lasso Cox regression based on microRNA expression. Here we propose a new score based on a 37-microRNA signature that is associated with AML and is able to predict survival more accurately than previous microRNA-based methods. 2024-09-05T07:27:06Z 2024-09-05T07:27:06Z 2024-08-06 journal article Ellson, I., Martorell-Marugán, J., Carmona-Sáez, P. et al. MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model. npj Genom. Med. 9, 40 (2024). https://doi.org/10.1038/s41525-024-00424-w https://hdl.handle.net/10481/93960 10.1038/s41525-024-00424-w eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Springer Nature